Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06840002
- Locations
- 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 160
- Registration Number
- NCT06837948
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- Conditions
- Early Triple Negative Breast Cancer
- Interventions
- Drug: Doxorubicin (hydrochloride)Drug: Olaparib (if approved/available locally)
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06829199
- Locations
- 🇺🇸
Optum Care Cancer Center ( Site 0004), Las Vegas, Nevada, United States
🇨🇳National Cheng Kung University Hospital ( Site 0901), Tainan, Taiwan
A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
- Conditions
- Lung CancerNon Small Cell Lung CancerBrain Metastases
- Interventions
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Latin American Cooperative Oncology Group
- Target Recruit Count
- 46
- Registration Number
- NCT06822543
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Conditions
- Breast NeoplasmsBreast Cancer
- Interventions
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 372
- Registration Number
- NCT06797635
- Locations
- 🇺🇸
Northwest Cancer Specialists (Compass Oncology) ( Site 8003), Tigard, Oregon, United States
🇺🇸Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003), Billings, Montana, United States
🇺🇸SCRI Oncology Partners ( Site 7000), Nashville, Tennessee, United States
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung CancerKRAS G12C Lung Cancer
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 600
- Registration Number
- NCT06793215
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Drug: Ifupinostat Hydrochloride for Injection
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- BeBetter Med Inc
- Target Recruit Count
- 416
- Registration Number
- NCT06792253
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
- Conditions
- Lung Neoplasm Malignant
- Interventions
- Biological: Pembrolizumab (neoadjuvant)Biological: Pembrolizumab (adjuvant)Drug: AntihistamineDrug: H2 receptor antagonistDrug: Steroid mouthwash (dexamethasone or equivalent)
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT06788912
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Careggi ( Site 0173), Firenze, Toscana, Italy
🇺🇸MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States
🇵🇱Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150), Gdansk, Pomorskie, Poland
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT06786312
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Fujian Provincial Hospital, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
- Conditions
- Advanced Solid Tumour
- Interventions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 210
- Registration Number
- NCT06783647
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Xiangyang Central Hospital, Xiangyang, Hubei, China
🇨🇳Mianyang Central Hospital, Mianyang, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.